Centogene raises a €25m in Series A financing

According to Centogene, the proceeds will be used to boost the company’s growth and expansion plans, aimed at establishing partnerships with major pharmaceutical companies in the areas of genetic testing and data-solutions. The Rostock-based company already commands the largest database and test portfolio for rare genetic diagnostics in the world including data from 120,000 patients from over 110 countries and over 3,100 single genes, including 200 panels. Additionally, the company offers whole exome and whole genome testing. Its proprietary CentoMD database allows Centogene to generate insights into the epidemiological basis of hereditary disorders and to link up genetic with functional data.

There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases.  This creates a tremendous market opportunity for us, comments Prof. Arndt Rolfs, MD, CEO and Founder of Centogene. Centogene’s genetics database coupled with its in-depth clinical knowledge positions the company perfectly to continue on its growth trajectory. It uniquely addresses the challenges of the pharmaceutical industry in a market that develops towards evidence-based and personalised medicine, said Guido Prehn, Partner at DPE Deutsche Private Equity.

Centogene said it aims at expanding into the US and Chinese markets and to grow in the MENA region and Latin America. The funding will enable the company to broaden its portfolio of biomarkers, companion diagnostics and tools for oncogenetics.